Literature DB >> 8791013

Determination of activity for nociceptin in the mouse vas deferens.

I P Berzetei-Gurske1, R W Schwartz, L Toll.   

Abstract

The recently discovered neuropeptide nociceptin was found to inhibit electrically induced contractions of the mouse vas deferens. Nociceptin and its 14-Tyr analog were each partial agonists, but with high affinity (ED50 of 20 nM). This activity was not opioid in nature, as it was not inhibited by either selective or non-selective opiate antagonists.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8791013     DOI： 10.1016/0014-2999(96)00238-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  13 in total

1.  Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens.

Authors:  R Bigoni; G Calo; R Guerrini; J W Strupish; D J Rowbotham; D G Lambert
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

2.  Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle.

Authors:  M Ho; A D Corbett; A T McKnight
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Modulation of (3)H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and beta-adrenoceptors in mouse tissues.

Authors:  A U Trendelenburg; S L Cox; V Schelb; W Klebroff; L Khairallah; K Starke
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.

Authors:  Katarzyna M Targowska-Duda; Akihiko Ozawa; Zachariah Bertels; Andrea Cippitelli; Jason L Marcus; Hanna K Mielke-Maday; Gilles Zribi; Amanda N Rainey; Brigitte L Kieffer; Amynah A Pradhan; Lawrence Toll
Journal:  Neuropharmacology       Date:  2020-03-06       Impact factor: 5.250

6.  Further characterization of the ORL1 receptor-mediated inhibition of noradrenaline release in the mouse brain in vitro.

Authors:  S Werthwein; U Bauer; M Nakazi; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Authors:  Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo
Journal:  Eur J Pharmacol       Date:  2016-10-22       Impact factor: 4.432

Review 8.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

Review 9.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

10.  Diabetes-induced changes in the morphology and nociceptinergic innervation of the rat uterus.

Authors:  Saeed Tariq; Syed M Nurulain; Hameed Rashed; Mohamed Lotfy; Starling Bright Emerald; Surya Koturan; Kornélia Tekes; Ernest Adeghate
Journal:  J Mol Histol       Date:  2015-11-20       Impact factor: 2.611
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.